X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare PLETHICO PHARMA with Dishman Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PLETHICO PHARMA vs DISHMAN PHARMA - Comparison Results

DISHMAN PHARMA 
   Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PLETHICO PHARMA DISHMAN PHARMA PLETHICO PHARMA/
DISHMAN PHARMA
 
P/E (TTM) x -1.1 25.1 - View Chart
P/BV x 0.0 3.3 0.5% View Chart
Dividend Yield % 0.0 0.7 -  

Financials

 PLETHICO PHARMA   DISHMAN PHARMA
EQUITY SHARE DATA
    PLETHICO PHARMA
Mar-14
DISHMAN PHARMA
Mar-16
PLETHICO PHARMA/
DISHMAN PHARMA
5-Yr Chart
Click to enlarge
High Rs395374 105.5%   
Low Rs31129 24.3%   
Sales per share (Unadj.) Rs604.4197.8 305.6%  
Earnings per share (Unadj.) Rs32.521.2 153.2%  
Cash flow per share (Unadj.) Rs51.334.7 147.8%  
Dividends per share (Unadj.) Rs02.00 0.0%  
Dividend yield (eoy) %00.8 0.0%  
Book value per share (Unadj.) Rs473.6179.9 263.2%  
Shares outstanding (eoy) m34.0880.69 42.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.41.3 27.7%   
Avg P/E ratio x6.611.9 55.3%  
P/CF ratio (eoy) x4.27.2 57.3%  
Price / Book Value ratio x0.51.4 32.2%  
Dividend payout %09.4 0.0%   
Avg Mkt Cap Rs m7,26220,306 35.8%   
No. of employees `000NA0.8 0.0%   
Total wages/salary Rs m1,5965,355 29.8%   
Avg. sales/employee Rs ThNM19,252.7-  
Avg. wages/employee Rs ThNM6,459.5-  
Avg. net profit/employee Rs ThNM2,064.1-  
INCOME DATA
Net Sales Rs m20,59815,961 129.1%  
Other income Rs m386265 145.6%   
Total revenues Rs m20,98416,226 129.3%   
Gross profit Rs m2,8184,103 68.7%  
Depreciation Rs m6421,091 58.9%   
Interest Rs m1,593944 168.7%   
Profit before tax Rs m9692,334 41.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m01 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-138624 -22.2%   
Profit after tax Rs m1,1071,711 64.7%  
Gross profit margin %13.725.7 53.2%  
Effective tax rate %-14.326.7 -53.5%   
Net profit margin %5.410.7 50.1%  
BALANCE SHEET DATA
Current assets Rs m18,87711,018 171.3%   
Current liabilities Rs m11,8969,517 125.0%   
Net working cap to sales %33.99.4 360.4%  
Current ratio x1.61.2 137.1%  
Inventory Days Days36110 32.5%  
Debtors Days Days19835 567.9%  
Net fixed assets Rs m9,86116,304 60.5%   
Share capital Rs m341161 211.1%   
"Free" reserves Rs m12,33112,907 95.5%   
Net worth Rs m16,13914,516 111.2%   
Long term debt Rs m4,7064,189 112.3%   
Total assets Rs m33,14629,805 111.2%  
Interest coverage x1.63.5 46.3%   
Debt to equity ratio x0.30.3 101.0%  
Sales to assets ratio x0.60.5 116.0%   
Return on assets %8.18.9 91.4%  
Return on equity %6.911.8 58.2%  
Return on capital %12.317.5 70.1%  
Exports to sales %21.424.8 86.2%   
Imports to sales %15.23.7 407.5%   
Exports (fob) Rs m4,4023,956 111.3%   
Imports (cif) Rs m3,136596 525.9%   
Fx inflow Rs m4,4024,952 88.9%   
Fx outflow Rs m3,184697 456.9%   
Net fx Rs m1,2194,255 28.6%   
CASH FLOW
From Operations Rs m2,4372,786 87.5%  
From Investments Rs m-6,265-1,529 409.8%  
From Financial Activity Rs m2,490-941 -264.6%  
Net Cashflow Rs m-1,337316 -422.6%  

Share Holding

Indian Promoters % 82.7 61.4 134.7%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 4.3 3.7 116.2%  
FIIs % 5.5 12.7 43.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 7.5 22.1 33.9%  
Shareholders   10,665 46,261 23.1%  
Pledged promoter(s) holding % 85.7 35.8 239.8%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PLETHICO PHARMA With:   DR. DATSONS LABS  BIOCON LTD  J.B.CHEMICALS  SUVEN LIFE  DR. REDDYS LAB  

Compare PLETHICO PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Global Stock Markets Chart Modest Gains(RoundUp)

Global financial markets ended the holiday shortened week with modest gains. The rally put behind days of decline as concerns regarding swift interest rates hikes were put to ease.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PLETHICO PHARMA SHARE PRICE


Jun 13, 2016 (Close)

TRACK PLETHICO PHARMA

  • Track your investment in PLETHICO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PLETHICO PHARMA

PLETHICO PHARMA 5-YR ANALYSIS

COMPARE PLETHICO PHARMA WITH

MARKET STATS